Clinical Highlights
Pregnancy Outcomes Following CD19 CAR-T Cell Therapy for Autoimmune Disease
Journal: New England Journal of Medicine (IF 84.5)
Corresponding Author: Georg Schett, Friedrich-Alexander University Erlangen-Nurnberg, Germany
DOI: 10.1056/NEJMc2607737
What was found. In a case series of 13 patients with autoimmune diseases — predominantly systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome — who had previously received autologous CD19 CAR-T cell therapy, 14 spontaneous pregnancies were reported. Eight pregnancies resulted in live births with normal neonatal parameters, five were ongoing at the time of reporting, and one was terminated. No autoimmune disease relapses occurred during any of the pregnancies. The median conditioning chemotherapy doses were cyclophosphamide 1,470 mg and fludarabine 133 mg. CAR-T cells were undetectable in all eight newborns.
Why it matters. This case series provides the first observational evidence that successful pregnancy is possible in patients who have received CD19 CAR-T therapy for autoimmune indications, without disease reactivation during gestation. The authors recommend establishing a dedicated pregnancy registry to systematically track outcomes in this emerging patient population.
Limitations. This is a case series (n = 13) with inherent selection and reporting biases. The findings are preliminary and should not be interpreted as evidence of safety for all patients. Prospective registry data and longer follow-up are needed before drawing conclusions about reproductive outcomes after CAR-T therapy for autoimmune disease.
Lisocabtagene Maraleucel plus Ibrutinib in Relapsed/Refractory CLL/SLL: TRANSCEND CLL 004 Primary Results
Journal: Blood (IF 23.9)
Corresponding Author: William G. Wierda, MD Anderson Cancer Center
DOI: 10.1182/blood.2026033565
Trial Identifiers: NCT03331198, NCT03435796
Study Design and Population. This analysis evaluated lisocabtagene maraleucel (liso-cel) at dose level 2 (100 x 10⁶ CAR+ T cells) combined with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The cohort had a median age of 64.5 years; 98% had high-risk cytogenetic abnormalities; 55% had progressed on both a BTK inhibitor and venetoclax; and patients had received a median of five prior lines of therapy.
Key Efficacy Data. At a median follow-up of 24.8 months, the complete response/complete response with incomplete count recovery (CR/CRi) rate was 45%, and the overall response rate was 86%. Median duration of response was 41.4 months and median progression-free survival (PFS) was 31.4 months.
Safety. Grade ≥3 adverse events included neutropenia (52%) and anemia (41%). Cytokine release syndrome (CRS) occurred in 80% of patients (grade ≥3, 4%). Neurologic events were reported in 41% (grade ≥3, 11%). Ibrutinib-related treatment-emergent adverse events occurred in 68% (grade ≥3, 43%).
CD4+ CAR-T Expansion Linked to Non-ICANS Neurotoxicity with Ciltacabtagene Autoleucel in Multiple Myeloma
Journal: Science Translational Medicine (IF 15.6)
Corresponding Author: Sham Mailankody, Memorial Sloan Kettering Cancer Center
DOI: 10.1126/scitranslmed.aed0039
An analysis of patients with relapsed/refractory multiple myeloma (RRMM) treated with ciltacabtagene autoleucel (cilta-cel) found that non-ICANS neurotoxicities (NINTs) were associated with marked CD4+ CAR-T cell expansion. The absolute lymphocyte count at peak expansion emerged as a strong predictive marker. Transcriptomic profiling revealed upregulation of inflammatory pathway genes in the relevant T-cell subsets. These findings suggest that monitoring CD4+ CAR-T expansion kinetics may help identify patients at elevated risk for NINTs and could inform risk-stratification strategies, though independent validation in larger cohorts is warranted.
Other Notable Clinical Reports
Low-Dose CAR-T Responsiveness Linked to Effector Memory-Like Phenotype. In the HD-CAR-1 basket trial (NCT03676504), investigators at Heidelberg University Hospital reported in Nature Communications that patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma who responded to low-dose CD19 CAR-T therapy showed enrichment of functional effector memory-like CAR-T cells. Conversely, an inhibitory myeloid cell state was associated with CAR-T cell exhaustion. Baseline T-cell counts and myeloid phenotypes in leukapheresis material may influence therapeutic outcomes.
Haploidentical CD7 CAR-T in Pediatric T-ALL. Franco Locatelli and colleagues at Bambino Gesu Children’s Hospital in Rome reported in the American Journal of Hematology on two pediatric patients with relapsed/refractory T-cell acute lymphoblastic leukemia treated with haploidentical allogeneic CD7 CAR-T cells (allo-PCART7) at 1 x 10⁶ CAR+ T cells/kg, without subsequent transplant. Both patients achieved CR with incomplete count recovery (CRi). One maintained remission for 20.1 months; the other experienced CD7-negative relapse and died. No graft-versus-host disease was observed. One patient developed grade 2 CRS and one had grade 4 septic shock; both experienced severe hematologic toxicity. These are preliminary findings from a two-patient case report and require validation in larger studies.
Intraventricular B7-H3 CAR-T in Pediatric CNS Tumors (BrainChild-03). Rebecca Ronsley and colleagues at Seattle Children’s Research Institute reported in Neuro-Oncology on a phase I trial (NCT04185038) of repeated intraventricular B7-H3 CAR-T cell infusions in children with CNS tumors, including DIPG, AT/RT, DMG, ependymoma, high-grade glioma, medulloblastoma, and pineoblastoma. Of 36 enrolled patients, 26 received treatment (median of 7 infusions per patient) at doses ranging from 1 x 10⁷ to 10 x 10⁷ CAR-T cells per infusion. Common adverse events included headache, fever, and nausea. Median overall survival was 11.5 months; two patients achieved partial responses. These early-phase data suggest feasibility of repeated intraventricular delivery, but efficacy signals remain modest and require confirmation in larger cohorts.
Standardized FDG-PET Interpretation in CAR-T-Treated DLBCL (DESCAR-T Registry). Laetitia Vercellino and colleagues at Hopital Saint-Louis in Paris analyzed 212 patients from the DESCAR-T registry in the European Journal of Nuclear Medicine and Molecular Imaging. Baseline total metabolic tumor volume (TMTV) > 30 cm³ was associated with poorer prognosis. At one month post-CAR-T, Deauville Score (DS) 1-3 versus 4-5 yielded a median PFS of 21.8 versus 1.8 months, respectively. DS 5 was associated with the poorest outcomes. Residual TMTV provided additional prognostic information beyond DS alone.
CRS and ICANS After Axi-cel or Brexu-cel: CIBMTR Database Analysis. Matthew J. Frigault and colleagues at Massachusetts General Hospital analyzed 927 patients (707 axi-cel, 220 brexu-cel) from the Center for International Blood and Marrow Transplant Research database, published in Transplantation and Cellular Therapy. The CRS rate was 82.6% (grade ≥2, 47%). ICANS occurred in 48.4% (grade ≥2, 71.5% of those affected). Tocilizumab was the primary treatment for CRS; corticosteroids were the primary treatment for ICANS. Use of prophylactic interventions increased over the study period.
Second-Line CAR-T vs Glofitamab-GemOx in LBCL: Matched Benchmarking. Gil Fridberg and colleagues at Tel Aviv University compared real-world second-line CD19 CAR-T outcomes (n = 75, of whom 26 met STARGLO eligibility criteria) against the Glofitamab-GemOx regimen in relapsed/refractory large B-cell lymphoma, published in Transplantation and Cellular Therapy. After matching to STARGLO inclusion criteria, median PFS was 8.8 versus 9.2 months (HR = 1.07, P = 0.82) and median OS was 19.1 versus 19.2 months (HR = 0.93, P = 0.83). Only 35% of real-world CAR-T patients met STARGLO trial eligibility, suggesting patients with high-risk features may derive greater benefit from earlier CAR-T use. These are retrospective comparisons and should be interpreted with caution.
Mechanistic and Translational Insights
Immature NK Subset Drives CAR-NK Dysfunction via Trogocytosis
Journal: Cancer Cell (IF 56.1)
Corresponding Authors: Ye Li, Katayoun Rezvani, MD Anderson Cancer Center
DOI: 10.1016/j.ccell.2026.06.017
Investigators at MD Anderson Cancer Center identified a CD16⁻C̄D161⁻ double-negative (DN) immature NK cell subset in umbilical cord blood-derived CAR-NK products that drives functional impairment through excessive trogocytosis. This DN subpopulation forms a trogocytic antigen pool (TAP) on the effector cell surface, which in turn triggers CAR-mediated fratricide and effector cell exhaustion.
Depletion of this DN subset restored antitumor activity in preclinical models, providing a rationale for modifying CAR-NK manufacturing protocols to exclude these cells. These findings are based on in vitro and preclinical models and have not yet been validated in clinical trials. If confirmed, this strategy could improve the consistency and potency of cord blood-derived CAR-NK products.
Prime-Edited Drug-Regulatable T-Cell Platform for Immune-Suppressive Environments
Journal: Blood (IF 23.9)
Corresponding Author: Miles B. Horton, Walter and Eliza Hall Institute of Medical Research, Australia
DOI: 10.1182/blood.2026033156
Researchers at the Walter and Eliza Hall Institute developed a multiplexed prime editing platform that introduces pathway-specific resistance mutations into therapeutic T cells, enabling their selective expansion in the presence of immunosuppressive agents. The system was designed for applications in subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and immune dysregulation syndromes, with HAVCR2 mutation correction as a proof-of-concept target. The approach may be applicable to CAR-T cells, gene-engineered T cells for other indications, and T-cell therapies requiring in vivo selection under pharmacological pressure. These are preclinical findings that require validation in relevant disease models before clinical translation can be considered.
CPNE1-Mediated STAT3-TGF-β Signaling Drives GPC3 CAR-T Resistance in Hepatocellular Carcinoma
Journal: Journal for ImmunoTherapy of Cancer (IF 11.7)
Corresponding Authors: Song Gao, Chaopin Yang, Jianchuan Xia, Sun Yat-sen University Cancer Center
DOI: 10.1136/jitc-2025-014430
In a preclinical study, investigators at Sun Yat-sen University Cancer Center showed that elevated CPNE1 expression in hepatocellular carcinoma (HCC) cells activates STAT3-TGF-β signaling, promoting cancer stemness and driving TGF-β secretion that induces CAR-T cell exhaustion. Silencing CPNE1 restored GPC3-directed CAR-T cell function in vitro. These results identify CPNE1 as a potential resistance mediator and suggest that combining GPC3 CAR-T therapy with CPNE1 or TGF-β pathway blockade could be a rational strategy for further preclinical evaluation. The findings are limited to in vitro models at this stage.
Additional Preclinical and Translational Findings
In Situ CAR Macrophage Generation for Triple-Negative Breast Cancer. Chen Ceshi, Li Fubing, Yan Zhiqiang, and colleagues reported in the Journal for ImmunoTherapy of Cancer a strategy using mannose-modified lipid nanoparticles to co-deliver CAR mRNA and R848 (a TLR7/8 agonist), generating pro-inflammatory CAR macrophages in situ. In syngeneic mouse and humanized TNBC models, including post-surgical recurrence and lung metastasis models, this approach enhanced antigen phagocytosis, promoted CD8+ T and NK cell infiltration, suppressed primary tumor growth, blocked recurrence, and prolonged survival. These are preclinical findings in animal models.
IL-10 Depletion in CAR-NK Cells Remodels the Tumor Microenvironment in Glioblastoma. Winfried S. Wels and colleagues at the Georg-Speyer-Haus Institute engineered ErbB2 (HER2)-targeted NK-92/5.28.z cells to express an intracellular anti-IL-10 antibody, reported in Molecular Therapy Oncology. Blocking IL-10 secretion did not impair CAR-NK cytotoxicity but promoted dendritic cell maturation, reduced M2 macrophage polarization, and reshaped the glioblastoma microenvironment toward a pro-inflammatory state. Antitumor activity was enhanced in preclinical models. These are early-stage preclinical findings.
Microsphere-Based Cytokine Profiling Identifies Baseline TGF-β1 as a CRS Biomarker in DLBCL. Sun Hongzhe and colleagues at the University of Hong Kong developed a lanthanide-encoded microsphere platform coupled with mass cytometry to profile 14 cytokines in 136 longitudinal samples from 32 DLBCL patients treated with CD19 CAR-T, published in Chemical Science. Baseline TGF-β1 levels were significantly associated with severe CRS (P = 0.001) and inferior event-free survival (P = 0.02). This is an exploratory biomarker analysis requiring validation in independent cohorts.
CAR-T vs Chemotherapy Assessment in Pancreatic Cancer Organoids. Investigators at Fudan University Shanghai Cancer Center reported in Pancreatology a Tet-On inducible RSPO1/WNT3A self-sustaining organoid platform to compare FOLFIRINOX chemotherapy against EPHA2-directed CAR-T cells across patient-derived pancreatic ductal adenocarcinoma organoids. Differential sensitivity was observed, and in vitro responses showed preliminary concordance with clinical disease trajectories. These are organoid-based preclinical findings with inherent limitations in recapitulating the in vivo tumor microenvironment.
Cis-Targeted IL-2 Mutein Enhances Engineered T-Cell Activity. Saar Gill and colleagues at the University of Pennsylvania developed an IL-2 mutein-antibody fusion molecule that selectively delivers IL-2 signals to engineered T cells in cis, published in Transplantation and Cellular Therapy. In a non-human primate model, this approach promoted CAR-T expansion and B-cell depletion without the need for lymphodepleting chemotherapy. These findings are from preclinical models and have not been tested in human trials.
Anti-Amyloid Beta CAR Microglia for Alzheimer’s Disease. Zhang Jin, Lei Anhua, and colleagues at Zhejiang University developed AXL-based CAR microglia-like cells derived from iPSCs (CAR-iMGLs) targeting amyloid-beta, published in Frontiers in Immunology. These cells enhanced Aβ phagocytosis, reduced pro-inflammatory cytokine production, and achieved efficient Aβ clearance in a mouse model without severe toxicity. These are early-stage preclinical findings in animal models.
Resveratrol Sensitizes Glioblastoma to NKG2D CAR-T Cells. Liu Maoxuan, Wan Xiaochun, Xu Shu, and colleagues at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, reported in Frontiers in Immunology that resveratrol upregulated NKG2D ligands on glioblastoma cells, potentially via a p53-related mechanism, thereby sensitizing tumor cells to NKG2D CAR-T-mediated killing. These are in vitro preclinical findings.
Review Article
Non-Viral Nanoparticle-Mediated In Vivo CAR Immune Cell Engineering. Qiu Min, Tong Zhenbo, Qijun Zheng, Zhu Tao, and colleagues at Fudan University reviewed non-viral nanoparticle strategies for in vivo generation of CAR-T, CAR-NK, and CAR-macrophage cells in Biomaterials. The review covers mRNA, circular RNA, self-amplifying RNA, and DNA delivery platforms with targeting strategies including CD3, CD4, CD5, CD7, and CD8, highlighting the potential for off-the-shelf immunotherapy approaches. As a review article, this does not present new primary data.
Limitations and Next Steps
The studies covered in this digest span a range of evidence levels, from case reports to registry analyses and phase I trials. Several key limitations should be noted:
· The pregnancy outcomes case series (NEJM) reports on 13 patients and requires prospective registry data before conclusions about reproductive safety after CAR-T can be drawn.
· The TRANSCEND CLL 004 data represent a single-arm analysis in a heavily pretreated population; randomized comparisons are needed to define the incremental benefit of adding ibrutinib to liso-cel in CLL.
· The cilta-cel neurotoxicity analysis identifies associations but does not establish causation; mechanistic studies and external validation are needed.
· Most translational studies (CAR-NK trogocytosis, CPNE1-mediated resistance, in situ CAR macrophage generation, prime-edited T cells) are based on preclinical models and have not been validated in clinical settings.
· The haploidentical CD7 CAR-T report in pediatric T-ALL is limited to two patients and should be considered exploratory.
· Several studies, including those published in Frontiers in Immunology and iScience, describe early-stage findings that require independent replication and peer review confirmation before translation.
Collectively, these reports reflect the breadth of CAR-T and related cellular immunotherapy research spanning autoimmune disease, hematologic malignancies, solid tumors, and neurodegenerative disorders. While translational momentum is evident, most novel findings remain at the preclinical or early clinical stage and warrant rigorous evaluation in larger, controlled studies.
References
1.Schett G, et al. Pregnancy after CD19 CAR-T cell therapy for autoimmune disease. N Engl J Med. 2026. DOI: 10.1056/NEJMc2607737.
2.Li Y, Rezvani K, et al. Depletion of an immature cord blood NK cell subset reverses trogocytosis-mediated CAR-NK dysfunction. Cancer Cell. 2026. DOI: 10.1016/j.ccell.2026.06.017.
3.Horton MB, et al. Prime-edited drug-regulatable T-cell therapy for immunosuppressive environments. Blood. 2026. DOI: 10.1182/blood.2026033156.
4.Wierda WG, et al. Liso-cel plus ibrutinib in R/R CLL/SLL: TRANSCEND CLL 004 primary results. Blood. 2026. DOI: 10.1182/blood.2026033565.
5.Mailankody S, et al. CD4+ CAR-T expansion and non-ICANS neurotoxicity with cilta-cel in MM. Sci Transl Med. 2026. DOI: 10.1126/scitranslmed.aed0039.
6.Schmitt M, Haas S, et al. A distinct CAR-T phenotype mediating response at low doses. Nat Commun. 2026. DOI: 10.1038/s41467-026-76068-4.
7.Locatelli F, et al. Haploidentical CD7 CAR-T in transplant-naive pediatric R/R T-ALL. Am J Hematol. 2026. DOI: 10.1002/ajh.70448.
8.Ronsley R, et al. Intraventricular B7-H3 CAR-T for pediatric CNS tumors: BrainChild-03 phase I trial. Neuro Oncol. 2026. DOI: 10.1093/neuonc/noag171.
9.Vercellino L, et al. Standardized FDG-PET interpretation in CAR-T-treated DLBCL: DESCAR-T registry. Eur J Nucl Med Mol Imaging. 2026. DOI: 10.1007/s00259-026-08055-2.
10.Frigault MJ, et al. CRS and ICANS after axi-cel or brexu-cel: CIBMTR analysis. Transplant Cell Ther. 2026. DOI: 10.1016/j.jtct.2026.07.029.
11.Fridberg G, et al. Matched benchmarking of second-line CAR-T vs Glofitamab-GemOx in LBCL. Transplant Cell Ther. 2026. DOI: 10.1016/j.jtct.2026.07.018.
12.Gao S, Yang C, Xia J, et al. CPNE1 drives GPC3 CAR-T resistance via STAT3-TGF-beta signaling in HCC. J Immunother Cancer. 2026. DOI: 10.1136/jitc-2025-014430.
13.Chen C, Li F, Yan Z, Sun L, et al. Co-delivery of CAR mRNA and TLR agonist for in situ CAR macrophage generation in TNBC. J Immunother Cancer. 2026. DOI: 10.1136/jitc-2026-015323.
14.Wels WS, et al. IL-10 depletion in CAR-NK cells remodels the glioblastoma microenvironment. Mol Ther Oncol. 2026. DOI: 10.1016/j.omton.2026.201285.
15.Sun H, et al. Microsphere-based cytokine profiling reveals dynamic immune features in CAR-T therapy. Chem Sci. 2026. DOI: 10.1039/d6sc03656b.
16.Qiu M, Tong Z, Zheng Q, Zhu T, et al. Non-viral nanoparticle-based in vivo CAR immune cell engineering. Biomaterials. 2026. DOI: 10.1016/j.biomaterials.2026.124492.
17.Gill S, et al. Cis-targeted IL-2 mutein enhances engineered T-cell antitumor activity. Transplant Cell Ther. 2026. DOI: 10.1016/j.jtct.2026.07.032.
18.Zhang J, Lei A, et al. Anti-amyloid beta CAR microglia for Alzheimer's disease. Front Immunol. 2026. DOI: 10.3389/fimmu.2026.1820099.
19.Liu M, Wan X, Xu S, et al. Resveratrol sensitizes glioblastoma to NKG2D CAR-T cells. Front Immunol. 2026. DOI: 10.3389/fimmu.2026.1831927.
20.Cheng H, Wang X, Yu X, Liu C, et al. Engineered self-sustaining organoids for comparing chemotherapy and CAR-T in pancreatic cancer. Pancreatology. 2026. DOI: 10.1016/j.pan.2026.07.013.